158 related articles for article (PubMed ID: 21934653)
41. The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells.
Longo PG; Laurenti L; Gobessi S; Sica S; Leone G; Efremov DG
Blood; 2008 Jan; 111(2):846-55. PubMed ID: 17928528
[TBL] [Abstract][Full Text] [Related]
42. Improved in vivo targeting of BCL-2 phenotypic conversion through hollow gold nanoshell delivery.
Morgan E; Gamble JT; Pearce MC; Elson DJ; Tanguay RL; Kolluri SK; Reich NO
Apoptosis; 2019 Jun; 24(5-6):529-537. PubMed ID: 30879165
[TBL] [Abstract][Full Text] [Related]
43. Direct cytosolic delivery of cargoes in vivo by a chimera consisting of D- and L-arginine residues.
Ma Y; Gong C; Ma Y; Fan F; Luo M; Yang F; Zhang YH
J Control Release; 2012 Sep; 162(2):286-94. PubMed ID: 22824782
[TBL] [Abstract][Full Text] [Related]
44. Synergism between a cell penetrating peptide and a pH-sensitive cationic lipid in efficient gene delivery based on double-coated nanoparticles.
Khalil IA; Kimura S; Sato Y; Harashima H
J Control Release; 2018 Apr; 275():107-116. PubMed ID: 29452131
[TBL] [Abstract][Full Text] [Related]
45. BDA-366, a putative Bcl-2 BH4 domain antagonist, induces apoptosis independently of Bcl-2 in a variety of cancer cell models.
Vervloessem T; Sasi BK; Xerxa E; Karamanou S; Kale J; La Rovere RM; Chakraborty S; Sneyers F; Vogler M; Economou A; Laurenti L; Andrews DW; Efremov DG; Bultynck G
Cell Death Dis; 2020 Sep; 11(9):769. PubMed ID: 32943617
[TBL] [Abstract][Full Text] [Related]
46. Stability of cell-penetrating peptide-morpholino oligomer conjugates in human serum and in cells.
Youngblood DS; Hatlevig SA; Hassinger JN; Iversen PL; Moulton HM
Bioconjug Chem; 2007; 18(1):50-60. PubMed ID: 17226957
[TBL] [Abstract][Full Text] [Related]
47. Farnesyltransferase inhibitor BMS-214662 induces apoptosis in B-cell chronic lymphocytic leukemia cells.
Marzo I; Pérez-Galán P; Giraldo P; López-Royuela N; Gómez-Benito M; Larrad L; Lasierra P; Rubio-Félix D; Anel A; Naval J
Leukemia; 2004 Oct; 18(10):1599-604. PubMed ID: 15356656
[TBL] [Abstract][Full Text] [Related]
48. A dual role for the anti-apoptotic Bcl-2 protein in cancer: mitochondria versus endoplasmic reticulum.
Akl H; Vervloessem T; Kiviluoto S; Bittremieux M; Parys JB; De Smedt H; Bultynck G
Biochim Biophys Acta; 2014 Oct; 1843(10):2240-52. PubMed ID: 24768714
[TBL] [Abstract][Full Text] [Related]
49. Novel polyethyleneimine-R8-heparin nanogel for high-efficiency gene delivery in vitro and in vivo.
Song L; Liang X; Yang S; Wang N; He T; Wang Y; Zhang L; Wu Q; Gong C
Drug Deliv; 2018 Nov; 25(1):122-131. PubMed ID: 29265887
[TBL] [Abstract][Full Text] [Related]
50. Tumor homing cell penetrating peptide decorated nanoparticles used for enhancing tumor targeting delivery and therapy.
Gao H; Zhang Q; Yang Y; Jiang X; He Q
Int J Pharm; 2015 Jan; 478(1):240-250. PubMed ID: 25448586
[TBL] [Abstract][Full Text] [Related]
51. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease.
Roberts AW; Seymour JF; Brown JR; Wierda WG; Kipps TJ; Khaw SL; Carney DA; He SZ; Huang DC; Xiong H; Cui Y; Busman TA; McKeegan EM; Krivoshik AP; Enschede SH; Humerickhouse R
J Clin Oncol; 2012 Feb; 30(5):488-96. PubMed ID: 22184378
[TBL] [Abstract][Full Text] [Related]
52. Octaarginine-modified liposomes enhance cross-presentation by promoting the C-terminal trimming of antigen peptide.
Nakamura T; Ono K; Suzuki Y; Moriguchi R; Kogure K; Harashima H
Mol Pharm; 2014 Aug; 11(8):2787-95. PubMed ID: 24901376
[TBL] [Abstract][Full Text] [Related]
53. Synthesis and biological evaluation of Apogossypolone derivatives as pan-active inhibitors of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins.
Wei J; Kitada S; Stebbins JL; Placzek W; Zhai D; Wu B; Rega MF; Zhang Z; Cellitti J; Yang L; Dahl R; Reed JC; Pellecchia M
J Med Chem; 2010 Nov; 53(22):8000-11. PubMed ID: 21033669
[TBL] [Abstract][Full Text] [Related]
54. Functionalized cell nucleus-penetrating peptide combined with doxorubicin for synergistic treatment of glioma.
Zhang L; Zhang Y; Tai L; Jiang K; Xie C; Li Z; Lin YZ; Wei G; Lu W; Pan W
Acta Biomater; 2016 Sep; 42():90-101. PubMed ID: 27370905
[TBL] [Abstract][Full Text] [Related]
55. Acylation of octaarginine: Implication to the use of intracellular delivery vectors.
Katayama S; Hirose H; Takayama K; Nakase I; Futaki S
J Control Release; 2011 Jan; 149(1):29-35. PubMed ID: 20144669
[TBL] [Abstract][Full Text] [Related]
56. EJP18 peptide derived from the juxtamembrane domain of epidermal growth factor receptor represents a novel membrane-active cell-penetrating peptide.
Eissa NG; Sayers EJ; Birch D; Patel SG; Tsai YH; Nielsen HM; Jones AT
Biochem J; 2020 Jan; 477(1):45-60. PubMed ID: 31820794
[TBL] [Abstract][Full Text] [Related]
57. Overcoming drug resistance by cell-penetrating peptide-mediated delivery of a doxorubicin dimer with high DNA-binding affinity.
Lelle M; Freidel C; Kaloyanova S; Tabujew I; Schramm A; Musheev M; Niehrs C; Müllen K; Peneva K
Eur J Med Chem; 2017 Apr; 130():336-345. PubMed ID: 28273560
[TBL] [Abstract][Full Text] [Related]
58. CyLoP-1: Membrane-active peptide with cell-penetrating and antimicrobial properties.
Ponnappan N; Budagavi DP; Chugh A
Biochim Biophys Acta Biomembr; 2017 Feb; 1859(2):167-176. PubMed ID: 27836642
[TBL] [Abstract][Full Text] [Related]
59. Conjugates of HA2 with octaarginine-grafted HPMA copolymer offer effective siRNA delivery and gene silencing in cancer cells.
Golan M; Feinshtein V; David A
Eur J Pharm Biopharm; 2016 Dec; 109():103-112. PubMed ID: 27702685
[TBL] [Abstract][Full Text] [Related]
60. High density of octaarginine stimulates macropinocytosis leading to efficient intracellular trafficking for gene expression.
Khalil IA; Kogure K; Futaki S; Harashima H
J Biol Chem; 2006 Feb; 281(6):3544-51. PubMed ID: 16326716
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
